Online inquiry

IVTScrip™ mRNA-Human ATP11A, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK25175MR)

This product GTTS-WK25175MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ATP11A protein. This product can be used in Ionocyte cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_015205.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 23250
UniProt ID P98196
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ATP11A, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK25175MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK16053MR IVTScrip™ mRNA-Human Aminopeptidase-N, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Aminopeptidase-N
GTTS-WK10905MR IVTScrip™ mRNA-Human ACAD11, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACAD11
GTTS-WK4880MR IVTScrip™ mRNA-Human CD156b, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD156b
GTTS-WK19670MR IVTScrip™ mRNA-Human ANAPC16, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANAPC16
GTTS-WK28436MR IVTScrip™ mRNA-Human ATAD2, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ATAD2
GTTS-WK15019MR IVTScrip™ mRNA-Human AHCY, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AHCY
GTTS-WK4144MR IVTScrip™ mRNA-Human AID, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AID
GTTS-WK12521MR IVTScrip™ mRNA-Human ADCY5, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCY5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW